Tirzepatide
Price on application
Tirzepatide is a first-in-class dual GIP/GLP-1 receptor agonist. By simultaneously activating both incretin receptor pathways, it achieves superior glycemic control and weight loss compared to selective GLP-1 agonists.
Research Profile
Tirzepatide is a 39-amino acid synthetic peptide that acts as a dual agonist of the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. Its sequence is based on native GIP with modifications for GLP-1 receptor cross-reactivity and a C-20 fatty diacid moiety for albumin binding. By engaging both incretin pathways, Tirzepatide provides synergistic effects on insulin secretion, glucagon suppression, appetite reduction, and energy expenditure. The SURPASS and SURMOUNT clinical trial programs demonstrated unprecedented efficacy: up to 22.5% body weight reduction and superior HbA1c lowering compared to semaglutide. FDA-approved as Mounjaro (diabetes) and Zepbound (obesity).
Technical Details
- Chemical Formula
- C225H348N48O68
- Synonyms
- Tirzepatide, Mounjaro, Zepbound, LY3298176
- Molecular Weight
- 4813.45 g/mol
- CAS Number
- 2023788-19-2
- Appearance
- Lyophilized White Powder
- Purity
- >98% (HPLC Verified)
- Shelf Life
- 36 months (Store at 2-8°C)